Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Description
The Kaufmännische Krankenkasse - KKH (hereinafter KKH) aims to conclude discount contracts in accordance with § 130a, paragraph 8, SGB V with all suitable pharmaceutical companies for the active substance(s) within the framework of a so-called "Open-House" procedure. By specifying uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the opportunity to conclude or join a discount contract in accordance with § 130a, paragraph 8, SGB V for the active substance(s) mentioned in the invitation to tender. Interested pharmaceutical companies can request the participation documents and the contract from the contact address ([email protected]).
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Medical equipments, pharmaceuticals and personal care products – Blutentnahme
EK-UNICO GmbHGermanyMedical equipments, pharmaceuticals and personal care productsVenepuncture, blood sampling devicesDeadline in 29 daysPublished on Oct 18, 2026
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pankreatin (ATC-Code nach WHO: A09AA02)
AOK PLUS - Die Gesundheitskasse für Sachsen und ThüringenGermanyPharmaceutical productsDeadline in 42 daysPublished on Oct 18, 2026
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Golimumab (ATC-Code nach WHO: L04AB06)
AOK PLUS - Die Gesundheitskasse für Sachsen und ThüringenGermanyPharmaceutical productsDeadline in 620 daysPublished on Oct 18, 2026
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Pegfilgrastim, ATC L03AA13 für die Zeit 01.01.2027 - 31.12.2027 (zzgl. Verlängerungsoption 1x12 Monate)
DAK-GesundheitGermanyPharmaceutical productsDeadline in 762 daysPublished on Oct 18, 2026